Gene Silencing in LNCaP and CWR22 cells with siRNA using DreamFect Gold transfection reagent; assay after 48H or 7 days follow-up.

LNCaP or CWR22 cells were transiently transfected with siRNA using DreamFect Gold transfection reagent. Assays were performed 48 H or 7 days after transfection.

This article demonstrates the high efficiency of DreamFect Gold from OZ Biosciences for gene silencing using siRNA in various cell lines.

article reference: Mol Cancer Ther. 2014 Oct 24.

Elevated LIM kinase 1 in non-metastatic prostate cancer reflects its role in facilitating androgen receptor nuclear translocation.

Mardilovich K, Gabrielsen M, McGarry L, Orange C, Patel R, Shanks E, Edwards J, Olson MF.
Abstract
Prostate cancer (PC) affects a large proportion of the male population, and is primarily driven by androgen receptor (AR) activity. First-line treatment typically consists of reducing AR signaling by hormone-depletion, but resistance inevitably develops over time. One way to overcome this issue is to block AR function via alternative means, preferably by inhibiting protein targets that are more active in tumors than in normal tissue. By staining PC tumor sections, elevated LIM kinase 1 (LIMK1) expression and increased phosphorylation of its substrate cofilin were found to be associated with poor outcome and reduced survival in patients with non-metastatic PC. A LIMK selective small molecule inhibitor (LIMKi) was used to determine whether targeted LIMK inhibition was a potential PC therapy. LIMKi reduced PC cell motility, as well as inhibiting proliferation and increasing apoptosis in androgen-dependent PC cells more effectively than in androgen-independent PC cells. LIMK inhibition blocked ligand-induced AR nuclear translocation, reduced AR protein stability and transcriptional activity, consistent with its effects on proliferation and survival acting via inhibition of AR activity. Furthermore, inhibition of LIMK activity increased alphaTubulin acetylation and decreased AR interactions with alphaTubulin, indicating that the role of LIMK in regulating microtubule dynamics contributes to AR function. These results indicate that LIMK inhibitors could be beneficial for the treatment of PC both by reducing nuclear AR translocation, leading to reduced proliferation and survival, and by inhibiting PC cell dissemination.

DreamFect Gold allows transfecting all types of nucleic acids with a very high efficiency. Due to its formulation, DreamFect™Gold delivers a large quantity of nucleic acids leading to higher protein expression compared to other transfection reagents. It is fully biodegradable and does not interfere with cellular mechanisms.